Intracoronary hemodynamic assessment of the physiologic significance of coronary lesions improves clinical outcomes in patients with coronary artery disease. Coronary flow velocity reserve, fractional flow reserve, instantaneous wave-free ratio, and index of microcirculatory resistance utilize sensor-mounted guidewires to approximate coronary flow. Coronary flow velocity reserve and fractional flow reserve rely on pharmacologic administration of adenosine to achieve hyperemia and diagnose epicardial lesion severity. As an adenosine-free index, the instantaneous wave-free ratio utilizes a wave-free period in the mid-late diastole during which resistance is constant and low to assess lesion significance. The index of microcirculatory resistance combines hyperemic pressure measurements with thermodilution to quantify microvascular resistance.
Introduction
Recent review articles have outlined the benefits of a nonangiography-based assessment of coronary artery disease. Matsuzawa and Lerman [1] discuss the ability of noninvasive measures of peripheral endothelial dysfunction to predict the presence of and complications from atherosclerotic coronary disease. Ahmed [2] provides an extensive overview of the assessment of coronary microvascular dysfunction by both noninvasive and invasive assessments. Rassi et al. [3] address practical uses for invasive assessment by fractional flow reserve and optical coherence topography in diagnosing and treating coronary disease. In this review, we expand upon nonangiographic assessment by focusing on emerging modalities to assess hemodynamic severity of coronary artery lesions in the cardiac catheterization lab. We summarize current and ongoing clinical trials addressing fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) and address their current and future roles in clinical practice. Furthermore, we discuss the data with regard to the index of microcirculatory resistance (IMR) and its potential as an invasive measure of microvascular disease and dysfunction.
Catheter-based assessment of coronary fluid hemodynamics has gained widespread translation to the clinical realm as an effective tool for diagnosing coronary artery disease severity [4] . Visual estimation of severity by angiography is an imperfect method with high interobserver variability and poor correlation with objective measurements such as quantitative coronary angiography and FFR [5, 6] . Whereas intravascular ultrasound and optical coherence tomography are available to improve anatomic assessment, the catheterization lab has also adopted physiologic assessment of lesion significance [7] . Translesional hemodynamics may be safely and reproducibly assessed by crossing a coronary lesion with a sensor-tipped guidewire to directly assess for ischemia, an assessment traditionally limited to noninvasive exercise and pharmacological stress testing [8] . Furthermore, large-scale, randomized clinical trials suggest that hemodynamic assessment of coronary artery lesions improves clinical outcomes [9] [10] [11] .
Coronary hemodynamics
Direct measurement of intracoronary hemodynamics is readily achieved in the cardiac catheterization lab. Pressure waves are transmitted through a fluid-filled catheter and analyzed using a pressure transducer or, in the case of pressure wires, measured by a pressure sensor 3 cm from the tip [12] . Similar coronary guidewires have been created that are mounted with thermistors [13] or Doppler sensors [14] for temperature or flow velocity assessment, respectively.
Ischemia is driven by a mismatch between myocardial oxygen demand and myocardial oxygen supply. Wall stress, heart rate, and contractility influence demand, whereas supply is related to arterial oxygen content and coronary blood flow. Increasing myocardial oxygen supply relies primarily on compensatory increases in coronary blood flow [15] . Coronary blood flow is best defined according to Poiseuille's law, wherein flow is determined by the perfusion pressure and resistance of a vessel (pressure = flow/resistance) [16] . Nearly all of the coronary vascular resistance in an undiseased vessel is due to microvascular resistance [17] . Resistance is influenced by both external compression, as occurs naturally in systole or pathologically in left-ventricular hypertrophy, and intrinsically by endothelial smooth muscle response to local metabolites and neural innervation [15] .
Coronary perfusion pressure is derived primarily from aortic blood pressure. When perfusion pressure decreases, arteriolar vasodilation maintains constant blood flow through a process termed autoregulation. In the setting of epicardial stenosis, the transcoronary pressure decreases but the flow is maintained through vasodilation up to the maximal threshold, at which point coronary flow cannot match demand and ischemia occurs [18] . Vasodilatory agents may be administered to achieve maximal dilation and minimize microvascular resistance. During hyperemia, coronary pressure has a linear correlation with coronary flow ( Fig. 1 ) [19, 20] . Coronary flow reserve (CFR), FFR, and iFR all utilize this principle of a correlative relationship between pressure and flow at points of minimal resistance to estimate the severity of a coronary artery lesion.
Coronary flow reserve
The degree to which coronary circulation dilates in response to pharmacologic stimulation is termed CFR [19] . CFR can be estimated through intracoronary Doppler velocity (CFVR) [21] [22] [23] or thermodilution flow measurements [24] [25] [26] . Absolute CFR is the ratio of maximal hyperemic flow to resting coronary flow and is therefore influenced by conditions that influence maximal flow [27] . Flow reserve is decreased in the setting of epicardial coronary stenosis because of higher resting vasodilation and is therefore correlated with epicardial resistance and severity of stenosis [28] .
However, the measurement is influenced by resting flow hemodynamics such as blood pressure and heart rate [29, 30] ( Fig. 1 ). Furthermore, CFR also is unable to distinguish between the influence of microvascular disease and epicardial disease on coronary flow [27] . The significant overlap between risk factors for epicardial coronary disease and microcirculatory dysfunction (i.e. diabetes, hypercholesterolemia, leftventricular hypertrophy) limits the efficacy of absolute coronary flow to isolate the significance of epicardial disease [31] . To mediate the influence of microvascular resistance, an indexed value (relative CFVR) has been used by calculating the ratio of the CFVR in a target vessel to the CFVR in an undiseased vessel. However, this requires the presence of a normal, undiseased vessel, and wiring it adds additional procedural time and risk [27] . The physiologic influences and procedural requirements have hindered the adoption of absolute or relative CFVR for wide-scale clinical use.
Fractional flow reserve Physiology
Myocardial FFR was developed as an index of lesion severity by comparing poststenosis blood flow in a vessel with a theoretical normal maximal flow in the same vessel distribution [32] . This is achieved by advancing an interventional pressure wire past the stenosis and deriving a ratio of the mean distal pressure (P d ) to the mean aortic pressure (P a ). The pressure gradient approximates coronary blood flow when maximal hyperemia is achieved by administration of nitroglycerin and adenosine [33, 34] . Unlike CFVR, FFR is independent of changes in hemodynamic or ionotropic conditions [30] .
Several limitations have been proposed. FFR relies on the assumption that pressure approximates flow in states in which microvascular resistance can be minimized and coronary venous flow is low [30] . Conditions that increase microvascular resistance or decrease the arteriolar vasodilatory reserve may limit the ability of adenosine to reliably achieve maximal hyperemia and may falsely influence the FFR value [35, 36] . Large, acute non-ST elevation myocardial infarction (non-STEMI) or STEMI damages coronary vasodilatory function [36] . In left-ventricular hypertrophy, the increase in myocardial mass is disproportionate to the growth of the microvasculature, increasing myocardial resistance and inhibiting maximal vasodilation [34] . Notably, these two subgroups have been excluded from clinical trials [9, 10] .
Elevated left-ventricular end-diastolic pressure restricts coronary flow during diastole and influences the pressure-flow relationship during hyperemia (Figs 1 and 2a) [37] [38] [39] . Furthermore, a paradoxical response to adenosine may be seen in severe stenosis or severely impaired microvascular resistance ( Fig. 2b ) [40] . Thus far, the influence of these subgroup characteristics on FFR values appears small, limiting their overall impact on clinical outcomes from an FFRbased revascularization strategy.
Clinical trials
Multiple clinical trials have evaluated the efficacy of an FFRbased treatment strategy in reducing clinical outcomes ( death, and acute myocardial infarction in the conservatively managed group due to an FFR greater than 0.75 remained extremely low, 3.3% at 5 years [41] .
The FAME trial randomly assigned 1005 patients with multivessel coronary artery disease to angiography-guided versus FFR-guided PCI or optimal medical therapy [44] .
Basing the PCI treatment strategy on an FFR of up to 0.80 resulted in a 5% absolute risk reduction (P = 0.02, number needed to treat 19) for all-cause death, myocardial infarction, and repeat revascularization. The group randomized to an FFR-based strategy also had lower mean numbers of stents placed (1.9 vs. 2.7, P < 0.001), lower procedural costs ($5332 vs. $6007, P < 0.001), and [44] [45] [46] . FAME 2 randomized 888 patients with stable coronary artery disease and an FFR of up to 0.80 and to PCI versus optimal medical therapy alone. Enrollment was halted prematurely when interim analysis found a significant reduction in the primary outcome of all-cause death, myocardial infarction, or urgent revascularization [hazard ratio 0.39, 95% confidence interval (0.26, 0.57)] among patients who underwent PCI. The risk reduction was driven primarily by a reduction in urgent revascularization (PCI group 4.0% vs. medical therapy group 16.3%, P < 0.001). There was no significant difference in outcomes between patients who underwent PCI based on an FFR of up to 0.80 and a registry cohort (n = 166) of patients who underwent medical therapy based on an FFR greater than 0.80 (95% confidence interval, 0.49, 3.39, P = 0.61) [47] .
These trials led to widespread adoption of invasive physiologic measurements for diagnosing ischemic lesions in current guidelines. Currently, the Society of Cardiovascular Angiography and Interventions Guidelines (2011) include a IIA recommendation for the use of FFR as an adjunct to angiography in assessing intermediate (50-70%) coronary lesions for revascularization therapy [48] . Similarly, the European Society of Cardiology 2014 Guidelines provide a IA recommendation for FFR to identify coronary lesions in the absence of prior stress testing and a IIA recommendation for FFR-guided PCI in patients with multivessel coronary artery disease [49] .
Future investigations
Several ongoing clinical trials are investigating further uses for FFR (Table 1) . FAME 3 (NCT02100722) is currently enrolling patients with multivessel coronary artery disease (≥50% stenosis) randomized to coronary artery bypass grafting versus an FFR-based PCI approach with a primary outcome of death, myocardial infarction, stroke, or repeat revascularization at 1 year [50] . The FORZA trial (NCT01824030) will randomize patients to FFR-guided versus optical coherence tomography-guided severity assessment for intermediate coronary lesions [51] . SYNTAX II is a multicenter trial (NCT02015832) that will utilize FFR (and iFR) to guide the PCI arm in a score-based approach to treat multivessel coronary artery disease. Secondary outcomes from MITNECB5 (NCT01972360) will add to the data comparing FFR with noninvasive testing, namely coronary CT, stress echocardiography, cardiac MRI perfusion, and technetium-99m SPECT [52] .
Instantaneous wave-free ratio Physiology
Over the last 3 years, there has been increasing interest in the use of hyperemia-free indices of severity. Hyperemia- Table 2 Clinical trials comparing the fractional flow reserve and the instantaneous wave-free ratio free hemodynamic assessment has been proposed to benefit over FFR or CFVR by obviating the need for the temporary discomfort from adenosine to patients, shortening procedural time, and decreasing costs [53, 54] .
The iFR is derived from a period of low and constant coronary resistance in mid to late diastole (Fig. 3) [53] . The mean pressure during this diastolic wave-free period is obtained distal to the lesion and indexed to the simultaneous aortic pressure. At this time point, the influence of coronary resistance is constant and low, allowing for pressure to correlate with coronary flow. Furthermore, isolation of the pressure measurement to a diastolic period improves variability [30, 53] by eliminating the interaction between the myocardium and coronary microvasculature in systole, during which the microvasculature is compressed and intracoronary resistance increases [53, 55, 56] .
Clinical trials
Multiple clinical trials have compared iFR with FFR. The ADenosine Vasodilator Independent Stenosis Evaluation (ADVISE) study formed the derivation cohort for the calculation of the iFR. The study compared iFR with FFR, finding relatively good agreement (R = 0.91, P < 0.0001) and the ability to predict an FFR less than 0.80 (C-statistic 0.93) [53] . However, this level of agreement has yet to be replicated in the multiple subsequent clinical trials, with correlation coefficients ranging from 0.77 to 0.91 (Table 2) [53, [57] [58] [59] [60] [61] . The largest study, RESOLVE, combined clinical trial (ADVISE, VERIFY) and institutional data to compare iFR, resting P d /P a , and hyperemic FFR at a core laboratory, ultimately evaluating 1593 lesions from 15 clinical sites. Interestingly, there was an extremely high correlation between nonhyperemic FFR (P d /P a ) and iFR measurements (R 2 = 0.95, P < 0.001); however, there was limited correlation with hyperemic FFR (R 2 = 0.66, P < 0.001). Using an iFR cutoff of 0.90 to predict an FFR of 0.80 classified 80% of the lesions appropriately [58] .
Although its correlation with FFR is limited, the diagnostic ability of iFR to diagnose ischemia may be similar to that of FFR. Utilizing a reference standard of myocardial perfusion scintigraphy, iFR appears to be similar in predicting ischemia when compared with FFR [iFR area under the curve (AUC) 0.81 vs. FFR AUC 0.85, P = 0.29; n = 85] [62]. The ability of iFR and FFR to predict physiologic significance, defined by hyperemic stenosis resistance, was also shown to be similar (iFR AUC 0.93 vs. FFR AUC 0.96, P = 0.48; n = 51) [63] . Coronary flow velocity reserve was found to have higher agreement with iFR than with FFR (r = 0.68 vs. 0.50, P < 0.001) [64] , although the use of CFVR as standard for ischemia is limited, as previously addressed [65] . Although there is suggestion of noninferiority from these small studies, definitive conclusions must be tempered pending further validation and larger sample-size studies.
Several studies have proposed novel uses for iFR. Nijjer et al. [66] described the role of iFR in the assessment of serial lesions and diffuse disease through the pressurewire pullback technique to predict the hemodynamic effect of PCI. Such a strategy may ultimately be valuable in decreasing the number of stents required or in shortening stent length. The use of iFR may help to rapidly document improvements in coronary hemodynamics following PCI, showing similar pre and post changes as FFR after PCI [67] . ADVISE II, a recently completed clinical trial, utilized a 'hybrid' iFR/FFR approach wherein treatment was based on iFR values of up to 0.86 (PCI) or at least 0.94 (medical therapy), with FFR utilized in the 'adenosine zone' of 0.86-0.93. Early reported results have boasted of a 94% classification match to FFR-guided therapy, saving 65.1% of patients from hyperemic therapy [68] .
Future investigations
The DEFINE REAL study (NCT02281110) will enroll 3000 patients in an observational registry to establish the ability of iFR to predict hemodynamic severity, as assessed by FFR less than 0.80, planning for the largest scale head-to-head assessment of correlation between iFR and FFR to date. Two currently registered trials plan to compare clinical outcomes based on an iFR-guided versus FFR-guided PCI strategy. iFR-Swedeheart (NCT02166736) will utilize 2000 patients with stable angina or acute coronary syndrome from the Swedish angiography and angioplasty registry to conduct a registry-based randomized clinical trial ultimately comparing 1 year outcomes of death, myocardial infarction, or unplanned revascularization between iFR and FFR groups.
Similarly, the DEFINE-FLAIR trial (NCT02053038) will randomly assign 2500 patients with intermediate lesions (40-70%) to an FFR-guided or iFRguided PCI strategy with plans to compare clinical outcomes (major adverse cardiac events) and cost between the two modalities. J-Define (NCT02002910) will further explore the cost-effectiveness of a hybrid FFR/IFR approach. SYNTAX II, PROSPECT II, ORBITA, and MITNEC will also utilize invasive physiologic assessments in their clinical protocols, with plans for comparisons between iFR and FFR in secondary analyses [52] .
Index of microcirculatory resistance
There is increasing interest in invasive hemodynamic assessment of microvascular dysfunction, an often unrecognized cause of cardiovascular symptoms and adverse cardiovascular outcomes [69] [70] [71] [72] . Whereas prior evaluations of microcirculatory resistance required Doppler flow/velocity measurements, IMR has been validated using a pressure and temperature sensor-mounted wire [73] . Maximal hyperemia is achieved with intravenous adenosine and the mean distal coronary pressure and mean transit time through thermodilution are measured. IMR is then calculated by multiplying the average P d by the average transit time [74] . In the setting of an epicardial stenosis, a measurement is also obtained during coronary balloon inflation to estimate coronary wedge pressure [75] .
The clinical applicability of IMR is still being defined. The largest focus of clinical investigations has been on the ability of IMR to predict the prognosis of patients undergoing PCI. For instance, Fearon et al. [75] showed that patients undergoing primary PCI for STEMI with culprit vessel IMR greater than 40 had an increased risk of death or rehospitalization for heart failure [hazard ratio 2.1 (1.1-1.41)]. Impressively, the effect of an elevated IMR on mortality was independent of clinical or procedural characteristics. In addition, IMR has been shown to predict periprocedural MI and outcomes in stable CAD in patients undergoing PCI [76, 77] . As we increase our understanding of the prognostic significance of microvascular dysfunction, IMR-tailored therapies or interventions may lead to improvements in outcomes of patients with coronary artery disease [78] .
Summary
Over 40 years of research on invasive coronary physiology has contributed to the emergence of intracoronary hemodynamic assessment as one of the most promising tools to diagnose ischemia and improve patient outcomes. FFR is a proven methodology with large-scale clinical data to support it. iFR and adenosine-free assessments show promise, the appropriateness of which will be addressed by ongoing investigations and clinical trials. IMR may finally draw attention to the clinical importance of microvascular disease. Regardless of the modality, the outlook for intracoronary hemodynamic assessment appears promising.
